Étiquette : essais cliniques

Entheogens, Katie Givens Kime, 2018

Entheogens Katie Givens Kime Institute of Practical Theology, University of Bern, Bern, Switzerland in D. A. Leeming (ed.), "Encyclopedia of Psychology and Religion", # Springer-Verlag GmbH Germany, part of Springer Nature 2018 Doi : 10.1007/978-3-642-27771-9_200181-1   Entheogen is a term coined in the late 1970s by a group of botanists and scholars which refers to any psychoactive agent which allows for “generating the divine within” (Ruck et al. 1979). Entheogens are psychedelic substances which, in adequate dosage under supportive conditions, are known to facilitate visionary, mystical, and/or spiritual experiences. Such substances include psilocybin, peyote, LSD (lysergic acid diethylamide), ibogaine, and ayahuasca. Typically of plant origin, entheogens are [...]

Lire la suite

Is There a Role for Cannabis in Mental Health Disorders ? Pauline Anderson & Charles P. Vega, 2019

Is There a Role for Cannabis in Mental Health Disorders ? Pauline Anderson & Charles P. Vega, Medscape, CME / ABIM MOC / CE Released : 12/13/2019 https://www.medscape.org/viewarticle/922367   Clinical Context The most common indication for the use of medicinal cannabis is pain, although the results of studies of cannabis products for chronic pain are mixed. Häuser and colleagues performed a review of systematic reviews of cannabis for chronic pain conditions, and their results were published in the October 15, 2017 issue of European Journal of Pain.[1] Reviewers evaluated 10 systematic reviews of cannabis for pain. Methodological quality was high in 4 of the reviews. There was [...]

Lire la suite

The epidemiology of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption, Alan K. Davis et al., 2018

The epidemiology of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption Alan K. Davis, Joseph P. Barsuglia, Rafael Lancelotta, Robert M. Grant, and Elise Renn Journal of Psychopharmacology, 2018, 32, (7), 779–792. doi : 10.1177/0269881118769063   Abstract Background/Aim : 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a psychoactive compound found in several plants and in high concentrations in Bufo alvarius toad venom. Synthetic, Toad, and Plant-sourced 5-MeO-DMT are used for spiritual and recreational purposes and may have psychotherapeutic effects. However, the use of 5-MeO-DMT is not well understood. Therefore, we examined patterns of use, motivations for consumption, subjective effects, and potential benefits and consequences [...]

Lire la suite

Bibliographie : Cannabidiol (CBD), Docteur Christian SUEUR, GRECC, février 2020.

Bibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, février 2020.     voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives

Lire la suite

Bibliographie : Kétamine, Dr Christian Sueur, GRECC, novembre 2019

Bibliographie : Kétamine Dr Christian Sueur, GRECC, novembre 2019   Kétamine en Psychiatrie .......................................................1 Kétamine et psychose ...........................................................2 Kétamine et traitement de la dépression ..............................3 Kétamine et prise en charge de l'idéation suicidaire ...........11 Kétamine et prise en charge des troubles psychotraumatiques (PTSD) ......12 Kétamine et addictions .........................................................13 Kétamine et sevrage des opiacés ..........................................14 Kétamine et prise en charge de la douleur ...........................15 Kétamine et prise en charge de la douleur chez l'enfant .....16 Pharmacologie de la kétamine ..............................................17 Neurophysiologie de la kétamine .........................................18 Neurotoxicologie de la kétamine ..........................................20 Kétamine et effets indésirables .............................................20  

Lire la suite

A systematic study of microdosing psychedelics, Vince Polito & Richard J. Stevenson, 2019

A systematic study of microdosing psychedelics RESEARCH ARTICLE Vince Polito, Richard J. Stevenson PLoS ONE, 2019, 14, (2), e0211023. Doi : 10.1371/journal.pone.0211023   Abstract The phenomenon of ‘microdosing’, that is, regular ingestion of very small quantities of psychedelic substances, has seen a rapid explosion of popularity in recent years. Individuals who microdose report minimal acute effects from these substances yet claim a range of long-term general health and wellbeing benefits. There have been no published empirical studies of microdosing and the current legal and bureaucratic climate makes direct empirical investigation of the effects of psychedelics difficult. In Study One we conducted a systematic, observational investigation of individuals [...]

Lire la suite

Psilocybin-Assisted Therapy : A Review of a Novel Treatment for Psychiatric Disorders, Kelan Thomas et al., 2017

Psilocybin-Assisted Therapy : A Review of a Novel Treatment for Psychiatric Disorders Kelan Thomas, Pharm.D., M.S., Benjamin Malcolm, Pharm.D., M.P.H., and Dan Lastra, B.S. Journal of Psychoactive Drugs, 2017 Doi : 10.1080/02791072.2017.1320734   Abstract Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in the default mode network has been associated with psycho-pathology, but psychedelic serotonin agonists like psilocybin may profoundly disrupt these dysfunctional neural network circuits and provide a novel treatment for psychiatric disorders. We have reviewed the current literature to investigate the efficacy and safety of psilocybin-assisted therapy for the treatment of psychiatric disorders. There were [...]

Lire la suite

Cannabis for Sleep: Short-Term Benefit, Long-Term Disruption ?, Michael Vlessides, 2020

Cannabis for Sleep: Short-Term Benefit, Long-Term Disruption ? Michael Vlessides Medscape, January 24, 2020 https://www.medscape.com/viewarticle/924202_print   Patients suffering from chronic pain who take medicinal cannabis to initiate and maintain sleep appear to experience short-term benefit, but long-term use may ultimately disrupt slumber, new research shows. Investigators found whole-plant medical cannabis use was associated with fewer problems with respect to waking up at night, but they also found that frequent medical cannabis use was associated with more problems initiating and maintaining sleep. "Cannabis may improve overall sleep in the short term," study investigator Sharon Sznitman, PhD, University of Haifa Faculty of Social Welfare and Health Sciences in Israel, [...]

Lire la suite

Malades de Parkinson à Marseille, ils vont tester le cannabis thérapeutique, La Provence, 24/1/2020

Malades de Parkinson à Marseille, ils vont tester le cannabis thérapeutique La Provence, 24/1/2020 https://www.laprovence.com/article/societe/5858706/avant-premiere-malades-de-parkinson-a-marseille-ils-vont-tester-le-cannabis-therapeutique.html transmis par principesactifs.fr La prise de cannabis peut-elle soulager certains symptômes moteurs et non-moteurs de la maladie de Parkinson ? "Nous avons de bonnes raisons de le penser mais nous avons besoin de données robustes pour le démontrer", sourit le Pr Olivier Blin, chef du service de pharmacologie clinique de la Timone, à Marseille. Grâce au soutien du centre d’excellence Dhune et de l’association France-Parkinson, son équipe, avec le service de neurologie et de pathologie du mouvement, le CNRS et l’Institut de neurosciences du CHU s’apprêtent à tester la prise de [...]

Lire la suite

Single Shot of Ketamine May Herald ‘Last Call’ for Problem Drinking, Deborah Brauser, 2019

Single Shot of Ketamine May Herald 'Last Call' for Problem Drinking Deborah Brauser Medscape, December 11, 2019 Medscape Medical News © 2019 https://www.medscape.com/viewarticle/922460?src=wnl_tp10n_200116_mscpedit&uac=292598PZ&impID=2238619&faf=1   An experimental treatment that includes a single infusion of ketamine may lead to long-term improvement in problem drinking, new research suggests. In an study of 90 heavy drinkers, those who received a single dose of intravenous (IV) ketamine plus cognitive behavioral therapy (CBT) that focused on reactivating drinking-related "maladaptive reward memories" (MRMs) significantly curbed the urge to drink and reduced alcohol intake  compared with those who received the ketamine alone or a placebo infusion. In addition, the combination group reduced their average weekly alcohol consumption by [...]

Lire la suite